Plasma Fractionation Market Size, Share & Trends Analysis Report By Product (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors), By Applications (Immunology, Hematology, Other), By End Use, By Region, and Segment Forecasts - 2035

PLASMA FRACTIONATION MARKET OVERVIEW

The plasma fractionation market size is expected to grow from USD 36479.05 million in 2025 to USD 38908.55 million in 2026 and is forecast to reach USD 47211.71 million by 2035 at 6.66% CAGR over 2026-2035.

Plasma fractionation is one of the significant components of this healthcare industry, with whole-blood plasma being separated into different components for distinct therapeutic applications. The business has achieved rapid growth based on the increasing incidence of chronic diseases, demand for plasma-derived products, and improvement in the technological setup of fractionation.

More patients with rare and chronic conditions who otherwise would have died are being treated because of the greater role played by the plasma fractionation industry. Plasma fractionation has allowed for the treatment of a huge number of disorders, which range from immune deficiencies to hemophilia and shock, by means of immunoglobulins, coagulation factors, and albumin, respectively. The medical infrastructure and awareness regarding these treatments are also becoming better, resulting in a continually increasing demand for plasma-derived products in the global market.

The United States Plasma Fractionation Market benefits from the world's largest plasma collection network, with more than 1,000 plasma donation centers supplying raw material for plasma-derived therapies. The U.S. accounts for over 60% of global source plasma collection, supporting the production of immunoglobulins, albumin, coagulation factors, and alpha-1 proteinase inhibitors. Rising diagnoses of primary immunodeficiency, hemophilia, and neurological disorders continue to increase demand for plasma-derived medicines. Manufacturers are expanding collection capacity, automating fractionation processes, and strengthening cold-chain logistics to improve product availability while maintaining stringent FDA quality and safety standards across plasma processing facilities.

• • 

    Download Free sample to learn more about this report.

PLASMA FRACTIONATION MARKET KEY FINDINGS

• Market Size and Growth: The Plasma Fractionation Market size was USD 34,201.24 Million in 2024, is projected to grow to USD 35,809.89 Million by 2025 and exceed USD 41,499.85 Million by 2033, with a CAGR of 6.66% from 2025 to 2033.

• Key Market Driver: The rising demand for immunoglobulin therapies is no joke—over 60% of global plasma-derived therapies are now immunoglobulins, with rising use in autoimmune and neurological disorders like CIDP and Guillain-Barré syndrome.

• Major Market Restraint: Plasma collection bottlenecks are real. In 2023 alone, plasma donation volumes dropped by 10% in the U.S., primarily due to labor shortages and regulatory complexities at donation centers.

• Emerging Trends: Hybrid fractionation technologies are picking up steam. There’s growing investment in single-use bioprocessing systems, which accounted for nearly 18% of new facility installations in 2024.

• Regional Leadership: North America leads the charge, contributing more than 40% of the global supply of source plasma, thanks largely to the sheer number of certified collection centers and favorable reimbursement policies.

• Competitive Landscape: The space is dominated by a handful of giants—5 companies control over 70% of the global market, including Grifols, CSL Behring, Takeda, Octapharma, and Kedrion.

• Market Segmentation: By product type, immunoglobulin held over 47% share of the market in 2024, followed by albumin and coagulation factors. Hospitals and clinics remain the largest end-user group by a wide margin.

• Recent Development: In 2024, Takeda opened a new $300 million plasma fractionation facility in Georgia, aiming to process up to 2 million liters of plasma annually—a clear move to future-proof against supply chain volatility.

GLOBAL CRISIS IMPACTS THE PLASMA FRACTIONATION MARKET - IMPACT OF COVID-19

"Aggravating Demand for Some Products and Supply Chain Disruptions Hit the Plasma Fractionation Industry as COVID-19 Pandemic Hits"

This was the case for the Plasma Fractionation Market in terms of COVID-19, mainly because of increased demand for immunoglobulins since the products may be used for severe cases. Although it increased the research into plasma therapies, contributions decreased from plasma donations due to the breaches within the supply chains, lockdowns, and unwillingness to donate that affected the availability of raw materials. In addition, treatment of patients suffering from COVID-19 depleted healthcare resources and lowered the demand for other plasma-derived products. Still, the industry has adapted to this fact by changing the collection protocols and embracing donations. For this reason, it gradually recovered and even surpassed the growth levels prior to the pandemic. This strength in the market led to recovery and growth.

LATEST TREND

"Technological Advancements in Fractionation Techniques to Drive Market Growth"

Some recent trends in Plasma Fractionation Market share include the high technological revolution in techniques of fractionation. New technologies applied have ensured that there is improved efficacy, yield, and purity of plasma-derived products. The recent technologies applying in the processes of chromatography, membrane separation techniques, and process automation form a comprehensive basis for improving the process of fractionation.These innovations, indeed, produce larger yields of valuable proteins extracted from plasma besides ensuring better safety and quality in the final products. There's the general trend toward the development of recombinant alternatives for plasma-derived products, following the mainstream approach while paradoxically challenging traditional fractionation methods. In addition, specialty products in this area of rare diseases and novel therapeutic plasma-derived protein applications are gaining much attention in the industry, which broadens scope and potential for the market.

• • 

    Download Free sample to learn more about this report.

SEGMENTATION OF PLASMA FRACTIONATION MARKET

BY PRODUCT

Based on products, the global market can be categorized into Coagulation factor concentrates, Albumin, Protease inhibitors, Other plasma products.

• Immunoglobulins: This market segment currently dominates as these are used for various purposes in treating immune-related diseases. Immunoglobulins are used in the treatment of primary immunodeficiency diseases, neurological diseases, and autoimmune diseases.

• Coagulation Factor Concentrates: The market for this product covers a majority part of the treatment of hemorrhagic diseases like hemophilia. The increase in this market is due to better diagnostic levels of hemorrhagic diseases, coupled with more alternatives for treatment since longer-acting factor concentrates are being offered to patients.

• Albumin: Primarily used in critical care and hypoalbuminemia, albumin remains an essential component in the Plasma Fractionation Market.

• Protease Inhibitors: This segment is smaller but growing due to the increasing interest in their potential therapeutics for rare genetic diseases and a variety of inflammatory conditions.

• Other Plasma Products: This segment consists of several specialty products that are plasma-derived; they cater to niche therapeutic areas and add to the diversity of the market as a whole.

BY APPLICATION

Based on application, the global market can be categorized  into neurology, immunology, hematology, critical care, pulmonology, and others.

• Neurology: Rising demand for plasma-derived products such as immunoglobulins in treating neurological disorders including CIDP and Guillain-Barré syndrome is driving growth in this market.

• Immunology: Among the plasma fractionation products, immuno globulins is a significant application. The increasing primary immunodeficiency disorders and growing incidence of autoimmune disease are fueling demand in this segment.

• Haematology: Plasma-derived coagulation factors are one of the most critical treatments presently available for bleeding disorders. Advances in diagnosis and new waves of novel therapies for haemophilia and von Willebrand disease are driving growth for this hematology segment.

• Critical Care: For the treatment of shock, burns and in surgical interventions, albumin and other plasma products are used. Current expansion of global infrastructure for critical care drives growth in the segment.

• Pulmonology: Use in pulmonary conditions such as alpha-1 antitrypsin deficiency is another scope that is expanding with plasma-derived products.

• Other Applications: These comprise various emerging as well as niche applications of plasma-derived products which have experienced some degree of market development and diversification.

MARKET DYNAMICS

Market dynamics covering driving as well as restraining factors along with opportunities and challenges state the market conditions.

DRIVING FACTORS

"Rising Prevalence of Chronic Diseases to Boost the Market"

A growing number of chronic diseases requiring plasma-derived treatments is one of the major drivers  in the Plasma Fractionation Market growth. An increased incidence of primary immunodeficiency disorders, hemophilia, and autoimmune diseases are now being seen more regularly, each of which can be partly laid at the doorstep of improved health care infrastructure and diagnostic capabilities. This trend is indeed observed more markedly in developing countries where enhanced health care access is provided. The larger patient population leads directly to an increase in plasma-derived product requirements and thus market growth.

"Advancements in Technology: Plasma Collection, Fractionation to Extend the Market"

Technological Innovation in Plasma Collection and Fractionation Processes: It has been another key driver of market growth. Advances in plasmapheresis techniques have made plasma donation safer and more efficient, hence encouraging more donors and increasing available supply of plasma. Generally, fractionation technologies such as chromatography and nanofiltration have led to improvements in yields and purity levels of plasma-derived products. It not only increases the quantity of available products but also their quality and safety, which increases the confidence among healthcare providers and patients.

RESTRAINING FACTOR

"High Cost of Plasma-Derived Products and Complex Regulatory Environment to Potentially Halt Market Growth"

One of the major hindering factors for the growth of the Plasma Fractionation Market is that plasma-derived products are very costly and have a highly complex, administered regulatory environment within which they are produced and distributed. High cost production due to resource-intensiveness: Collecting plasma and ensuring that fractionation is done as well as product safety will be very resource-intensive, meaning this does translate to high cost production. Normally, such costs are passed on to the patients, meaning that some therapies could be priced out of reach to people in regions without comprehensive coverage. More so, mandatory scrutiny and regulation requirements ought to be for safety purposes, but long development timelines and costs of compliance arise from such regulation. All these factors combined together can limit market access and growth, primarily within the emerging economies with restricted health care budgets.

OPPORTUNITY

"Growing Demand for Plasma Derivatives Presents Opportunity for Market Expansion"

The Plasma Fractionation Market is characterized by vast and exciting opportunities resulting from the ever-increasing applications of plasma-derived products. Scientific discoveries increasingly reveal new therapeutic application of hitherto known plasma components and identify new proteins with potential medical application. For instance, immunoglobulins are increasingly being considered for treating Alzheimer's disease and certain forms of cancers. Also, albumin is also being researched for drug delivery and inclusion in regenerative medicine. All these emerging applications are likely to significantly enhance the market size of plasma-derived products with significant revenues generation and more research within the company.

CHALLENGES

"Plasma shortages and ethical concerns can be a challenge that growth within the market may face."

Despite the adoption of plasma fractionation over the last decade, the plasma supply shortage continues to be a significant challenge in the market. And there is always an ethical consideration that revolves around plasma supply shortages. Moreover, a supply of donated plasma is generally insufficient to meet the demand for plasma-derived products. Another problem is that a few countries, particularly the United States, provide a significant portion of the world's plasma supply. It brings a geographical concentration which raises questions concerning both the resilience of supply chains and the equity of access all over the world to plasma-derived therapies. Moreover, ethical issues raise in compensated plasma collection, practiced in some countries but prohibited in others from concerns with exploitation of vulnerable populations. The need for more plasma collection in respect of the balance of ethical considerations with the equity of global access to plasma-derived products has become an immense challenge for the industry.

• • 

    Download Free sampleto learn more about this report.

•  

PLASMA FRACTIONATION MARKET REGIONAL INSIGHTS

NORTH AMERICA

North America is the largest and fastest-growing region in the Plasma Fractionation Market. Its dominance is largely attributed to a high prevalence of chronic diseases requiring plasma-derived therapies, well-established healthcare infrastructure, and an efficient plasma collection network. The United States Plasma Fractionation Market is one of the biggest players in the market. It is the source for a large share of the world's plasma supply. A relatively benevolent regulatory environment coupled with an acceptable level of compensation for donors makes the country one of the greatest sources of donors. Thus, a large donor base produces a good steady supply of raw material for fractionation. Other factors, such as the presence of major companies that produce plasma fractions and upcoming research and development in the region, also contribute to its leadership market.

EUROPE

The Plasma Fractionation Market in Europe is another significant part of it. The market is marked by high-class healthcare from the physical to clinical care and assures that patients under different treatment options are not devoid of safety. Well-developed health care systems are present in the region, and people are becoming more aware of rare diseases that can be treated through plasma-derived products. There is also the question of plasma self-sufficiency in Europe, as many countries rely on imported plasma, mainly from the United States. Hence the initiatives at improving the domestic plasma collection and fractionation capacities. With strict regulatory standards, the European market gives a quality product but, in turn, makes it even more challenging to get into the market and secure product approval.

ASIA PACIFIC

The Asia Pacific region is gradually emerging as one of the enlarging markets for plasma fractionation as a result of progress in health infrastructure and increased diagnosis rates for chronic diseases, among other increasing healthcare expenditure. Countries such as China and India, due to their large population and growing middle class, constitute significant market growth opportunities for the plasma fractionation industry. There is an emerging interest in developing local plasma collection and fractionation capacities in these countries, reducing dependency on importation. But a lot of unmet needs still exist, especially with regard to awareness, accessibility, and affordability of plasma-derived therapies for most parts of the region.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

The Plasma Fractionation Market remains influenced by major industry participants who innovate strategically and broaden their markets. They invest highly in R&D associated with advances in fractionation technology and new plasma-derived products, besides further extending their plasma collection networks to be able to sustain a steady supply of raw material. Most focus on geographical expansion, especially into emerging markets, to tap new patient populations. Other than this, they are building strategic alliances and acquisitions that help gain them higher market share and add more products to the portfolio. High-tech manufacturing facilities and high-grade standards of the company enhance quality product safety and efficacy-a reason for confidence among healthcare professionals and patients.

LIST OF TOP PLASMA FRACTIONATION COMPANIES

• CSL (Australia)
• Grifols S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• Kedrion S.p.A (Italy)
• LFB (France)
• Biotest AG (Germany)
• Sanquin (Netherlands)
• China Biologic Products Holdings, Inc. (China)
• Bio Products Laboratory Ltd. (U.K.)
• Japan Blood Products Organization (Japan)

KEY INDUSTRY DEVELOPMENT

March 2024: CSL launched a new state-of-the-art plasma fractionation facility in Marburg, Germany. The facility will be used to upgrade CSL's production capacity for plasma-derived therapies as the company looks to meeting the ever-growing global demand for life-critical products. The facility had the latest fractionation technologies in line with the best standards of quality and safety; such efficiencies are only bound to further cement CSL's position as a leader in the plasma fractionation industry.

Five Recent Developments (2023-2025)

• 2025: Grifols introduced a new subcutaneous immunoglobulin therapy designed to improve patient convenience and treatment adherence through less frequent administration.
• 2024: A leading plasma manufacturer expanded its North American plasma collection network by adding 50 new donation centers, increasing collection capacity by 25%.
• 2024: GC Biopharma advanced construction of Indonesia's first plasma fractionation facility, strengthening regional manufacturing capacity for plasma-derived medicines.
• 2023: Grifols received U.S. regulatory clearance for expanded plasma collection operations, enhancing the supply of source plasma for fractionation.
• 2023: Bio Products Laboratory (BPL) partnered with CSI Pharmacy to expand distribution of its Gammaplex immune globulin therapy across the United States.

REPORT COVERAGE

The Plasma Fractionation Market will grow because increasing numbers of people have chronic diseases, and new techniques of fractionation also get introduced. However, increases in the use of plasma-derived products are expected, though production shortages and regulatory complications pose some challenges. Strong need for plasma therapies ensures steady demand. Innovation continues, strategic expansion, and plasma collection networks get improvements, so drive the industry. Finally, added value from the globalization of healthcare coupled with the value that plasma therapies bring to sustainable growth supports these trends. New therapeutic applications may evolve from the research done on plasma fractionation, and with that comes much enhanced future prospects for the Plasma Fractionation Market.